Tumor infiltrating lymphocytes as a prognostic and predictive biomarker in breast cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tumor infiltrating lymphocytes (TILs) have been recognized in various cancers and may reflect a host immune response to malignant cells. TILs are a heterogeneous population of various types of mononuclear cells, including CD8 or CD4 + T cells and their subsets, B cells, myeloid derived suppressor cells (MDSC), macrophages, and other cells. Immunosuppressive factors in the tumor microenvironment (TME) that inhibit recruitment and function of TILs include immunosuppressive cells, cytokines secreted by tumor or mesenchymal cells, and co-inhibitory ligands expressed by tumor cells. Despite this complex interplay of immune cells and the TME, higher TIL density is associated with favorable prognosis in certain breast cancer subtypes, including HER2 overexpressing cancers, and "triple negative" cancers that do not express the estrogen and progesterone receptors or overexpress HER2. TILs infiltrating the tumor stroma (sTILs) are associated with higher rates of complete pathologic response to neoadjuvant chemotherapy, decreased recurrence and improved survival in early stage triple negative and HER2-positive breast cancer treated with adjuvant systemic therapy. An international working group has published guidelines on reporting TILs in pathology specimens. In this chapter we review the composition of TILs, mechanisms of immune evasion, recommendations for TILs measurement, and data supporting use of TILs as a prognostic and predictive biomarker in breast cancer.

Original languageEnglish (US)
Title of host publicationMolecular Pathology of Breast Cancer
PublisherSpringer International Publishing
Pages167-186
Number of pages20
ISBN (Electronic)9783319417615
ISBN (Print)9783319417592
DOIs
StatePublished - Jan 1 2016

Fingerprint

Tumor-Infiltrating Lymphocytes
Biomarkers
Breast Neoplasms
Neoplasms
Tumor Microenvironment
Immunosuppressive Agents
Immune Evasion
Cellular Microenvironment
T-Lymphocyte Subsets
Progesterone Receptors
Antigen-Antibody Complex
Estrogen Receptors
B-Lymphocytes
Macrophages
Guidelines
Pathology
Cytokines
Ligands
Recurrence
Drug Therapy

Keywords

  • CD4
  • CD8
  • MDSC
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tumor infiltrating lymphocytes as a prognostic and predictive biomarker in breast cancer. / Janakiram, Murali; Khan, Hina; Fineberg, Susan A.; Zang, Xingxing; Sparano, Joseph A.

Molecular Pathology of Breast Cancer. Springer International Publishing, 2016. p. 167-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{1977ee18d8c24a2a890c034c9477efcc,
title = "Tumor infiltrating lymphocytes as a prognostic and predictive biomarker in breast cancer",
abstract = "Tumor infiltrating lymphocytes (TILs) have been recognized in various cancers and may reflect a host immune response to malignant cells. TILs are a heterogeneous population of various types of mononuclear cells, including CD8 or CD4 + T cells and their subsets, B cells, myeloid derived suppressor cells (MDSC), macrophages, and other cells. Immunosuppressive factors in the tumor microenvironment (TME) that inhibit recruitment and function of TILs include immunosuppressive cells, cytokines secreted by tumor or mesenchymal cells, and co-inhibitory ligands expressed by tumor cells. Despite this complex interplay of immune cells and the TME, higher TIL density is associated with favorable prognosis in certain breast cancer subtypes, including HER2 overexpressing cancers, and {"}triple negative{"} cancers that do not express the estrogen and progesterone receptors or overexpress HER2. TILs infiltrating the tumor stroma (sTILs) are associated with higher rates of complete pathologic response to neoadjuvant chemotherapy, decreased recurrence and improved survival in early stage triple negative and HER2-positive breast cancer treated with adjuvant systemic therapy. An international working group has published guidelines on reporting TILs in pathology specimens. In this chapter we review the composition of TILs, mechanisms of immune evasion, recommendations for TILs measurement, and data supporting use of TILs as a prognostic and predictive biomarker in breast cancer.",
keywords = "CD4, CD8, MDSC, Tumor infiltrating lymphocytes",
author = "Murali Janakiram and Hina Khan and Fineberg, {Susan A.} and Xingxing Zang and Sparano, {Joseph A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-41761-5_12",
language = "English (US)",
isbn = "9783319417592",
pages = "167--186",
booktitle = "Molecular Pathology of Breast Cancer",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Tumor infiltrating lymphocytes as a prognostic and predictive biomarker in breast cancer

AU - Janakiram, Murali

AU - Khan, Hina

AU - Fineberg, Susan A.

AU - Zang, Xingxing

AU - Sparano, Joseph A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tumor infiltrating lymphocytes (TILs) have been recognized in various cancers and may reflect a host immune response to malignant cells. TILs are a heterogeneous population of various types of mononuclear cells, including CD8 or CD4 + T cells and their subsets, B cells, myeloid derived suppressor cells (MDSC), macrophages, and other cells. Immunosuppressive factors in the tumor microenvironment (TME) that inhibit recruitment and function of TILs include immunosuppressive cells, cytokines secreted by tumor or mesenchymal cells, and co-inhibitory ligands expressed by tumor cells. Despite this complex interplay of immune cells and the TME, higher TIL density is associated with favorable prognosis in certain breast cancer subtypes, including HER2 overexpressing cancers, and "triple negative" cancers that do not express the estrogen and progesterone receptors or overexpress HER2. TILs infiltrating the tumor stroma (sTILs) are associated with higher rates of complete pathologic response to neoadjuvant chemotherapy, decreased recurrence and improved survival in early stage triple negative and HER2-positive breast cancer treated with adjuvant systemic therapy. An international working group has published guidelines on reporting TILs in pathology specimens. In this chapter we review the composition of TILs, mechanisms of immune evasion, recommendations for TILs measurement, and data supporting use of TILs as a prognostic and predictive biomarker in breast cancer.

AB - Tumor infiltrating lymphocytes (TILs) have been recognized in various cancers and may reflect a host immune response to malignant cells. TILs are a heterogeneous population of various types of mononuclear cells, including CD8 or CD4 + T cells and their subsets, B cells, myeloid derived suppressor cells (MDSC), macrophages, and other cells. Immunosuppressive factors in the tumor microenvironment (TME) that inhibit recruitment and function of TILs include immunosuppressive cells, cytokines secreted by tumor or mesenchymal cells, and co-inhibitory ligands expressed by tumor cells. Despite this complex interplay of immune cells and the TME, higher TIL density is associated with favorable prognosis in certain breast cancer subtypes, including HER2 overexpressing cancers, and "triple negative" cancers that do not express the estrogen and progesterone receptors or overexpress HER2. TILs infiltrating the tumor stroma (sTILs) are associated with higher rates of complete pathologic response to neoadjuvant chemotherapy, decreased recurrence and improved survival in early stage triple negative and HER2-positive breast cancer treated with adjuvant systemic therapy. An international working group has published guidelines on reporting TILs in pathology specimens. In this chapter we review the composition of TILs, mechanisms of immune evasion, recommendations for TILs measurement, and data supporting use of TILs as a prognostic and predictive biomarker in breast cancer.

KW - CD4

KW - CD8

KW - MDSC

KW - Tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85009674531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009674531&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-41761-5_12

DO - 10.1007/978-3-319-41761-5_12

M3 - Chapter

SN - 9783319417592

SP - 167

EP - 186

BT - Molecular Pathology of Breast Cancer

PB - Springer International Publishing

ER -